Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 25 min ago
Peer-reviewedLicence not statedThe Cochrane Database of Systematic Reviews

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer

  • Ya Gao1,2,3
  • Ming Liu3,4
  • Lun Li5
  • Junhua Zhang6
  • Fujian Song7
  • Jinhui Tian3
7 affiliations
  1. 1Department of Medical Dataology, School of Public Health, Cheeloo College of Medicine Shandong University Jinan China
  2. 2National Institute of Health and Medical Big Data Jinan China
  3. 3Evidence-Based Medicine Center, School of Basic Medical Sciences Lanzhou University Lanzhou City China
  4. 4Lee Kong Chian School of Medicine Nanyang Technological University Sigapore Singapore
  5. 5Department of Breast Cancer The Second Xiangya Hospital, Central South University Changsha China
  6. 6Evidence-Based Medicine Center Tianjin University of Traditional Chinese Medicine Tianjin China
  7. 7Norwich Medical School University of East Anglia Norwich UK
Read full textDOICite

Related

  1. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, Sehhoon Park, Gyeong-Won Lee +16
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
    Nolan Holley, Syed Ahmad, Gary Monroe +4
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes
    Eleonora Camilleri, Nikola Vladic, Cornelia Englisch +10
    Research and Practice in Thrombosis and HaemostasisPeer-reviewedCC BYFull textOncologyDOAJ
  4. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, MD, PhD, Sehhoon Park, MD, PhD, Gyeong-Won Lee, MD, PhD +16
    JTO Clinical and Research ReportsPeer-reviewedCC BY-NC-NDFull textOncologyDOAJEurope PMCPMC
  5. Hepatic arterial infusion chemotherapy in combination with immune checkpoint inhibitors and targeted therapy for advanced intrahepatic cholangiocarcinoma.
    Li Zhang, Chengfeng Liu, Juan Zhang +6
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gao2026immune,
  title = {{Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer}},
  author = {Ya Gao and Ming Liu and Lun Li and Junhua Zhang and Fujian Song and Jinhui Tian},
  journal = {The Cochrane Database of Systematic Reviews},
  year = {2026},
  month = may,
  doi = {10.1002/14651858.cd015072.pub3},
  url = {https://doi.org/10.1002/14651858.cd015072.pub3},
}
RIS
TY  - JOUR
TI  - Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
AU  - Ya Gao
AU  - Ming Liu
AU  - Lun Li
AU  - Junhua Zhang
AU  - Fujian Song
AU  - Jinhui Tian
PY  - 2026
DA  - 2026/05/21
JO  - The Cochrane Database of Systematic Reviews
DO  - 10.1002/14651858.cd015072.pub3
UR  - https://doi.org/10.1002/14651858.cd015072.pub3
SN  - 1469-493X
ER  -